Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Herzog, Thomas J
AIM2CERV, NCT02853604 / 2015-004844-20: Study of ADXS11-001 in Participants With High Risk Locally Advanced Cervical Cancer	Terminated	3	110	Europe, Canada, US, RoW	ADXS11-001, Placebo	Advaxis, Inc., Gynecologic Oncology Group	High Risk Cervical Cancer, Advanced Cervical Cancer	07/19	07/19
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected	Active, not recruiting	3	358	Europe, Canada, US, RoW	Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)	Novartis Pharmaceuticals	Ovarian Cancer	04/23	06/25
CG03, NCT03949283: Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer	Active, not recruiting	3	150	US	ChemoID Assay, Chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), Standard Chemotherapy, Chemotherapy	Cordgenics, LLC	Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer	06/24	12/24
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian	Completed	2	150	US, RoW	Paclitaxel, Afuresertib, LAE002	Laekna Limited	Platinum-resistant Ovarian Cancer	07/23	06/24
Woeste, Lisa
NCT04595838: A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis	Completed	N/A	176	US	Chemo Mouthpiece, Oral cryotherapy delivery device, Best Supportive Care only	Chemo Mouthpiece	Oral Mucositis	05/23	05/23